CNTN — Tharimmune, Inc.

CNTN closed at $2.05 (+0.49%) on Oct 29, 2026. Active shelf registration (S-3, Jan 2026). Float: 75.9M shares. Latest SEC filing: 8-K on Oct 29, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for CNTN in the TickerWise workspace.

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 2
• Website: http://tharimmune.com

Latest SEC filings for CNTN

• 2026-10-298-K
• 2026-10-274
• 2026-10-274
• 2026-10-274
• 2026-10-274
• 2026-10-274
• 2026-10-274
• 2026-10-274
• 2026-10-274
• 2026-08-148-K

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.